TheraCryf
plc
("TheraCryf", the "Company" or the "Group")
Issue of Equity and Total
Voting Rights
Alderley Park, UK - 14 Nov 2024:
TheraCryf plc (AIM: TCF), the clinical
stage drug development company focussing on oncology and
neuropsychiatry, announces that the Company has
issued 2,275,527 new ordinary shares of 0.25 pence each in the
capital of the Company ("Ordinary Shares") in lieu of professional
fees.
Application will be made for
2,275,527 Ordinary Shares to be admitted to trading on AIM
("Admission"). Admission is expected to occur on or around 20
November 2024 and the Ordinary Shares will, on issue, rank pari
passu in all respects with the Company's existing Ordinary
Shares.
On Admission, the Company will have
a total of 429,622,422 Ordinary Shares in issue. No Ordinary Shares
are held in treasury. The figure of 429,622,422 may be used by the
Company's shareholders as the denominator in the calculations by
which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company under
the Financial Conduct Authority's Disclosure, Guidance and
Transparency Rules.
-Ends-
Enquiries
|
TheraCryf plc
Dr Huw Jones, CEO
Toni Hänninen, CFO
Dr Helen Kuhlman, CBO
|
+44 (0)1625 315
090
enquiries@theracryf.com
|
|
Cavendish Capital Markets (NOMAD and Broker)
Geoff Nash / Teddy Whiley / Rory Sale (Corporate
Finance)
Nigel Birks / Harriet Ward (ECM)
|
+44 20 7220
0500
|
|
Vigo Consulting
Rozi
Morris
|
+44 207 7390 0230
theracryf@vigoconsulting.com
|
About TheraCryf
TheraCryf is a clinical stage drug
development company focussing on oncology and neuropsychiatry. The
Company has a broad clinical and preclinical pipeline in
indications including glioblastoma*, neurodevelopmental disorders,
addiction, anxiety and narcolepsy* [*orphan
indications].
Its strategy is to generate
compelling data sets to preclinical and/or clinical proof of
concept and partner its clinical programmes with mid-size to large
pharma for larger trials and commercialisation, including Stalicla SA, in neurodevelopmental disorders.
The Company has sourced know how for programmes
from companies such as Shire (now Takeda).
TheraCryf has worked with and has
ongoing collaborations with major universities and hospitals such
as the University of Manchester, La Sapienza (Università di Roma),
the Erasmus Medical Centre, Rotterdam, Kings College London and the
University of Michigan.
The Company has its headquarters and
registered office at Alderley Park, Cheshire. It is listed on AIM
in London and trades under the ticker symbol TCF.
For further information, please
visit: www.theracryf.com